NCT05394701View on ClinicalTrials.gov

Comparing the Pharmacological Profile of Formulations Containing Omega 3 Fatty Acids

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Pharmacokinetics
Interventions
DIETARY_SUPPLEMENT

Omega-3 LipoMicel® soft gels

A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)

DIETARY_SUPPLEMENT

RxOmega-3 soft gels (Enteric)

A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)

DIETARY_SUPPLEMENT

Omega-3 Complete soft gels (Non-Enteric)

A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)

Trial Locations (1)

V3N4S9

ISURA, Burnaby

All Listed Sponsors
lead

Factors Group of Nutritional Companies Inc.

INDUSTRY